Iterum Therapeutics plc (ITRMF) Total Current Liabilities (2017 - 2025)

Iterum Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $6.4 million for Q3 2025.

• In Q3 2025, Total Current Liabilities fell 65.62% year-over-year to $6.4 million; the TTM figure through Sep 2025 stood at $6.4 million (down 65.62% YoY), while the FY2024 annual figure was $17.6 million, up 30.23% from the prior year.
• Total Current Liabilities for Q3 2025 stood at $6.4 million, up from $5.5 million in the prior quarter.
• The five-year high for Total Current Liabilities was $43.8 million in Q1 2021, with the low at $3.6 million in Q1 2025.
• The 5-year median for Total Current Liabilities is $12.9 million (2021), against an average of $14.6 million.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities soared 128.22% in 2024, then tumbled 79.61% in 2025.
• Iterum Therapeutics' Total Current Liabilities stood at $12.9 million in 2021, then slipped by 29.96% to $9.1 million in 2022, then jumped by 49.14% to $13.5 million in 2023, then surged by 30.23% to $17.6 million in 2024, then slumped by 63.48% to $6.4 million in 2025.
• Business Quant data shows ITRMF's Total Current Liabilities at $6.4 million in Q3 2025, $5.5 million in Q2 2025, and $3.6 million in Q1 2025.